Literature DB >> 32711984

Computed tomography density is not associated with pathological tumor invasion for pure ground-glass nodules.

Fangqiu Fu1, Yang Zhang1, Shengping Wang2, Yuan Li3, Zezhou Wang4, Hong Hu1, Haiquan Chen5.   

Abstract

OBJECTIVE: Pure ground-glass nodules are considered to be radiologically noninvasive in lung adenocarcinoma. However, some pure ground-glass nodules are found to be invasive adenocarcinoma pathologically. This study aims to identify the computed tomography parameters distinguishing invasive adenocarcinoma from adenocarcinoma in situ and minimally invasive adenocarcinoma.
METHODS: From May 2011 to December 2015, patients with completely resected adenocarcinoma appearing as pure ground-glass nodules were reviewed. To evaluate the association between computed tomography features and the invasiveness of pure ground-glass nodules, logistic regression analyses were conducted.
RESULTS: Among 432 enrolled patients, 118 (27.3%) were classified as adenocarcinoma in situ, 213 (49.3%) were classified as minimally invasive adenocarcinoma, 101 (23.4%) were classified as invasive adenocarcinoma. There was no postoperative recurrence for patients with pure ground-glass nodules. Logistic regression analyses demonstrated that computed tomography size was the only independent radiographic factor associated with adenocarcinoma in situ (odds ratio, 47.165; 95% confidence interval, 19.279-115.390; P < .001), whereas computed tomography density was not (odds ratio, 1.002; 95% confidence interval, 0.999-1.005; P = .127). Further analyses revealed that there was no distributional difference in computed tomography density among 3 groups (P = .173). Even after propensity score matching for adenocarcinoma in situ/minimally invasive adenocarcinoma and invasive adenocarcinoma, no significant difference in computed tomography density was observed (P = .741). The subanalyses for pure ground-glass nodules with 1 cm or more in size also indicated similar results.
CONCLUSIONS: In patients with pure ground-glass nodules, computed tomography size was the only radiographic parameter associated with tumor invasion. Measuring computed tomography density provided no advantage in differentiating invasive adenocarcinoma from adenocarcinoma in situ and minimally invasive adenocarcinoma.
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CT density; CT size; lung adenocarcinoma; pure ground-glass opacity

Mesh:

Year:  2020        PMID: 32711984     DOI: 10.1016/j.jtcvs.2020.04.169

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Predicting the histological invasiveness of pulmonary adenocarcinoma manifesting as persistent pure ground-glass nodules by ultra-high-resolution CT target scanning in the lateral or oblique body position.

Authors:  Hua Ren; Fufu Liu; Lei Xu; Fan Sun; Jing Cai; Lingwei Yu; Wenbin Guan; Haibo Xiao; Huimin Li; Hong Yu
Journal:  Quant Imaging Med Surg       Date:  2021-09

2.  Part-solid tumours: at the border of 2 worlds.

Authors:  Paul E Van Schil; Lawek Berzenji
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-01-18

Review 3.  Management of Ground-Glass Nodules: When and How to Operate?

Authors:  Young Tae Kim
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

4.  Radiomics for identifying lung adenocarcinomas with predominant lepidic growth manifesting as large pure ground-glass nodules on CT images.

Authors:  Ziqi Xiong; Yining Jiang; Di Tian; Jingyu Zhang; Yan Guo; Guosheng Li; Dongxue Qin; Zhiyong Li
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

5.  Application of three-dimensional (3D) reconstruction in the treatment of video-assisted thoracoscopic complex segmentectomy of the lower lung lobe: A retrospective study.

Authors:  Xinyu Wang; Qing Wang; Xindi Zhang; Hang Yin; Yujie Fu; Min Cao; Xiaojing Zhao
Journal:  Front Surg       Date:  2022-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.